Infection and Drug Resistance (2020-09-01)

Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report

  • Zhu Y,
  • Zhu R,
  • Liu K,
  • Li X,
  • Chen D,
  • Bai D,
  • Luo J,
  • Liu Y,
  • Zhang Y,
  • Li L,
  • Hu J,
  • Xu D,
  • Liu Y,
  • Zhao RC

Journal volume & issue
Vol. Volume 13
pp. 3295 – 3300

Abstract

Read online

Yue Zhu,1,* Rongjia Zhu,2,* Kun Liu,3,* Xin Li,1 Dezhong Chen,4 Dunyao Bai,5 Jieli Luo,5 Yixun Liu,6 Yan Zhang,7 Li Li,8 Junfang Hu,9 Dayong Xu,10 Yan Liu,10 Robert Chunhua Zhao2,11 1Stem Cell Lab, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, People’s Republic of China; 2Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, People’s Republic of China; 3Otorhinolaryngology, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, People’s Republic of China; 4Department of Respiratory and Critical Care Medicine, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, People’s Republic of China; 5Molecular Laboratory, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, People’s Republic of China; 6Gonadal Biology Research Group, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, People’s Republic of China; 7National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, People’s Republic of China; 8The Ministry of Science and Education, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, People’s Republic of China; 9Department of Pharmacy, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, People’s Republic of China; 10Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, People’s Republic of China; 11School of Life Sciences, Shanghai University, Shanghai 200444, People’s Republic of China*These authors contributed equally to this workCorrespondence: Robert Chunhua ZhaoInstitute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, People’s Republic of ChinaEmail [email protected] LiuStem Cell Lab, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, People’s Republic of ChinaEmail [email protected]: COVID-19 (coronavirus disease 2019) has become a global public health emergency since patients were first detected in Wuhan, China, in December 2019. Currently, there are no satisfying antiviral medications and vaccines available.Case Presentation: We reported the treatment process and clinical outcome of a 48-year-old man critically ill COVID-19 patient who received transfusion of allogenic human umbilical cord mesenchymal stem cells (UC-MSCs).Conclusions: We proposed that UC-MSC transfusion might be a new option for critically ill COVID-19. Although only one case we were shown, more similar clinical cases are inquired for further evidence providing the potential effectiveness of UC-MSC treatment.Keywords: COVID-19, UC-MSCs, critically ill, cell transplantation, case report

Keywords